Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Stach

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
RMD Open|August 30, 2017
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritisJürgen Braun, Xenofon Baraliakos, Kay-Geert Hermann, et al.
Journal of Leukocyte Biology|September 29, 2006
The influence on the immunomodulatory effects of dying and dead cells of Annexin VLuis E Munoz, Sandra Franz, Friederike Pausch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2016
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsMegan E B Clowse, Daniel J Wallace, Richard A Furie, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
RMD Open|August 30, 2017
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritisJürgen Braun, Xenofon Baraliakos, Kay-Geert Hermann, et al.
Journal of Leukocyte Biology|September 29, 2006
The influence on the immunomodulatory effects of dying and dead cells of Annexin VLuis E Munoz, Sandra Franz, Friederike Pausch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2016
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsMegan E B Clowse, Daniel J Wallace, Richard A Furie, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Pageof 2